Vir Biotechnology
VIR on Nasdaq. Vir Biotechnology develops medicines for infectious diseases and cancer to treat patients. Market value $2.0bn.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-20.21 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 24 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$11.60 a share, 141% above its 1-year low
Over the past year the price has ranged from $4.82 to $11.94.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $1.1bn | $1.6bn | $86m | $74m | $69m |
| Operating margin | |||||
| Operating margin | 38.4% | 51.6% | -794.0% | -791.3% | -699.2% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.13bn | 0.13bn | 0.14bn | 0.14bn | 0.17bn |
Health checks
- Free cash flow positive1 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsShrinking, 2.1% a year
- Buying back its own sharesNo, 27% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $239 million last quarter, up 19583% on a year ago.
- Profit: $80 million, after a loss of $111 million a year ago.
- It loses 92 cents on each $1 of sales, compared with 3192 cents a year earlier.
- 22% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 2 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $2m |
| December 2024 | $12m |
| March 2025 | $3m |
| June 2025 | $1m |
| September 2025 | $240,000 |
| December 2025 | $64m |
| March 2026 | -$29,000 |
| June 2026 | $239m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$214m |
| December 2024 | -$105m |
| March 2025 | -$121m |
| June 2025 | -$111m |
| September 2025 | -$163m |
| December 2025 | -$43m |
| March 2026 | -$126m |
| June 2026 | $80m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 23 February 2026
- Next quarterly (estimated, 10-Q)
- 4 November 2026
Who owns it
None of the long-term investors we follow own it. 237 funds in all.
Largest holders overall
- BlackRock$211mAdded
- ARCH Venture Management$129m
- Vanguard Portfolio Management$117mAdded
- SB Investment Advisers (uk)$112m
- State Street$102mAdded
- GSK$87m
- Vanguard Capital Management$65mAdded
- Point72 Asset Management, L.P.$58mAdded
- Geode Capital Management$34mAdded
- Dimensional Fund Advisors LP$32mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- BlackRock, Inc.Passive investor10.8%Since 31 March 2025
- Robert NelsenPassive investorat least 8.5%(filed with 7 related holders)Since 27 February 2026
- Vanguard Portfolio ManagementPassive investor6.8%+1.1 ptsSince 30 June 2026
- SB Investment Advisers (UK) LimitedPassive investorat least 6.5%−2.9 pts(filed with 2 related holders)Since 31 March 2026
- STATE STREET CORPORATIONPassive investor5.9%Since 30 June 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 10.8% | 31 March 2025 | |
Robert Nelsen Passive investor | at least 8.5% (filed with 7 related holders) | 27 February 2026 | |
Vanguard Portfolio Management Passive investor | 6.8%+1.1 pts | 30 June 2026 | |
SB Investment Advisers (UK) Limited Passive investor | at least 6.5%−2.9 pts (filed with 2 related holders) | 31 March 2026 | |
STATE STREET CORPORATION Passive investor | 5.9% | 30 June 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 7 sold $3m, $3m of it under preset trading plans.
- Napolitano JanetDirectorSoldunder a preset trading plan
- Date
- 1 June 2026
- Shares
- 3,200
- Price
- $9.45
- Value
- $30,240
- Sabatini BrentSVP, Chief Accounting OfficerSoldunder a preset trading plan
- Date
- 1 June 2026
- Shares
- 379
- Price
- $9.45
- Value
- $3,582
- SATO VICKI LDirectorSoldunder a preset trading plan
- Date
- 1 May 2026
- Shares
- 22,000
- Price
- $10.05
- Value
- $221,100
- De Backer MariannePresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 6 April 2026
- Shares
- 72,559
- Price
- $9.16
- Value
- $664,640
- SATO VICKI LDirectorSoldunder a preset trading plan
- Date
- 1 April 2026
- Shares
- 22,000
- Price
- $9.07
- Value
- $199,540
- Sabatini BrentSVP, Chief Accounting OfficerSoldunder a preset trading plan
- Date
- 23 March 2026
- Shares
- 7,711
- Price
- $9.12
- Value
- $70,324
- SATO VICKI LDirectorSoldunder a preset trading plan
- Date
- 2 March 2026
- Shares
- 22,000
- Price
- $9.50
- Value
- $209,096
- Eisner MarkEVP and Chief Medical OfficerSoldunder a preset trading plan
- Date
- 25 February 2026
- Shares
- 1,889
- Price
- $9.82
- Value
- $18,550
- de Verneuil VaninaEVP, General Counsel, Corp SecSoldunder a preset trading plan
- Date
- 25 February 2026
- Shares
- 13,700
- Price
- $9.82
- Value
- $134,534
- SATO VICKI LDirectorSoldunder a preset trading plan
- Date
- 24 February 2026
- Shares
- 42,377
- Price
- $9.75
- Value
- $413,278
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 1 June 2026 | Napolitano Janet Director | Sold under a preset trading plan | 3,200 | $9.45 | $30,240 |
| 1 June 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sold under a preset trading plan | 379 | $9.45 | $3,582 |
| 1 May 2026 | SATO VICKI L Director | Sold under a preset trading plan | 22,000 | $10.05 | $221,100 |
| 6 April 2026 | De Backer Marianne President and CEO, Director | Sold under a preset trading plan | 72,559 | $9.16 | $664,640 |
| 1 April 2026 | SATO VICKI L Director | Sold under a preset trading plan | 22,000 | $9.07 | $199,540 |
| 23 March 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sold under a preset trading plan | 7,711 | $9.12 | $70,324 |
| 2 March 2026 | SATO VICKI L Director | Sold under a preset trading plan | 22,000 | $9.50 | $209,096 |
| 25 February 2026 | Eisner Mark EVP and Chief Medical Officer | Sold under a preset trading plan | 1,889 | $9.82 | $18,550 |
| 25 February 2026 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sold under a preset trading plan | 13,700 | $9.82 | $134,534 |
| 24 February 2026 | SATO VICKI L Director | Sold under a preset trading plan | 42,377 | $9.75 | $413,278 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
- Sales have shrunk: 2.1% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.